Endo issued subpoena regarding Lidoderm promotion

Share this article:
Endo Pharmaceuticals was issued a subpoena by the Department of Health and Human Services regarding the promotion of its post-shingles pain patch Lidoderm, requesting documents from 1999 to the present related to the company's knowledge of off-label uses for the treatment.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Pharmaceutical

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.